StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report report published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Down 2.8 %
Shares of NASDAQ PULM opened at $2.12 on Friday. The firm’s 50-day moving average price is $2.10 and its two-hundred day moving average price is $1.97. The stock has a market capitalization of $7.74 million, a P/E ratio of -0.88 and a beta of 0.99. Pulmatrix has a 52-week low of $1.55 and a 52-week high of $2.75.
Pulmatrix (NASDAQ:PULM – Get Free Report) last posted its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) EPS for the quarter. Pulmatrix had a negative net margin of 95.18% and a negative return on equity of 46.86%. The business had revenue of $1.55 million during the quarter.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Stories
- Five stocks we like better than Pulmatrix
- How to Calculate Inflation Rate
- How Much Can You Make in Stocks in One Month?
- Business Services Stocks Investing
- This Is the Top Large-Cap Stock Insiders Are Buying
- What Are Dividend Challengers?
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
